Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE ACETATE versus SYNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE ACETATE versus SYNACORT.
DEXAMETHASONE ACETATE vs SYNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
Synthetic corticosteroid with potent glucocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
0.5-9 mg/day orally in divided doses every 6-12 hours; intravenously or intramuscularly as dexamethasone sodium phosphate; typical anti-inflammatory dose 0.75-9 mg/day. For cerebral edema: IV loading dose 10 mg, then 4 mg every 6 hours. For COVID-19: 6 mg IV or orally once daily for up to 10 days.
100 mg intravenously every 8 hours for 24 hours, then 50 mg intravenously every 8 hours for 48 hours, followed by 25 mg intravenously every 8 hours for 72 hours.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in adults; slightly prolonged in neonates (approximately 12-24 hours) and patients with hepatic impairment. Clinical context: Duration of HPA axis suppression may exceed the presence of measurable drug; single dose typically suppresses cortisol for 24-36 hours.
Terminal elimination half-life is 2.5–3.5 hours; clinically, this short half-life requires multiple daily dosing for sustained effects.
Renal (primarily as glucuronide and sulfate conjugates) and biliary/fecal (minor). Approximately 65-80% of a dose is excreted in urine within 24 hours as 20-beta-dihydrodexamethasone (inactive) and conjugated metabolites; about 10-15% appears in feces. Less than 5% is excreted unchanged.
Primarily renal (80% as metabolites, 20% unchanged); minor biliary/fecal (<5%).
Category D/X
Category C
Corticosteroid
Corticosteroid